<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04436822</url>
  </required_header>
  <id_info>
    <org_study_id>CIP330</org_study_id>
    <nct_id>NCT04436822</nct_id>
  </id_info>
  <brief_title>Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics</brief_title>
  <official_title>Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in
      subjects age 2 - 80 years, for the span of 170 hours (7 days).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in
      subjects age 2 - 80 years, for the span of 170 hours (7 days).

      This is a multi-center study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>20% (±20 mg/dL [1.1 mmol/L] when SG less than (&lt;) 80 mg/dL [4.4 mmol/L]) Agreement, by age group and insertion location</measure>
    <time_frame>170 hours</time_frame>
    <description>Sensor values will be compared to YSI™* plasma glucose values during YSI™* FSTs. A within 20% mean agreement rate (±20 mg/dL [1.1 mmol/L] when SG less than (&lt;) 80 mg/dL [4.4 mmol/L]), µ, between sensor values and YSI™* plasma glucose values during YSI™* FST days will be evaluated.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">376</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Subjects with diabetes wearing DS5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects wearing DS5 over 7 days and participating in FSTs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Glucose Monitoring</intervention_name>
    <description>CGM and frequent sample testing</description>
    <arm_group_label>Subjects with diabetes wearing DS5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Individual is 2 - 80 years of age at time of enrollment.

          2. Subject has a clinical diagnosis of type 1 or type 2 diabetes for a minimum of 6
             months duration as determined via medical record/ source documentation by an
             individual qualified to make a medical diagnosis.

          3. If subject is participating in YSI™* FST , subject has adequate venous access as
             assessed by investigator or appropriate staff.

          4. Subjects participating in the high and low glucose challenges must have an insulin
             carbohydrate ratio(s) and insulin sensitivity factor(s). Subjects without ratios may
             participate under observation only.

        Exclusion Criteria:

          1. Subject will not tolerate tape adhesive in the area of sensor placement as assessed by
             a qualified individual.

          2. Subject has any unresolved adverse skin condition in the area of sensor or device
             placement (e.g., psoriasis, rash, Staphylococcus infection).

          3. Subject is actively participating in an investigational study (e.g., drug or device)
             wherein he/she has received treatment from an investigational study (drug or device)
             in the last 2 weeks prior to Visit 1. (Please note participation in an observational
             study is acceptable.)

          4. Subject is female of child-bearing potential and has a pregnancy screening test that
             is positive.

          5. Subject is a sexually active female of child-bearing potential and is not using a form
             of contraception deemed reliable by investigator.

          6. Subject is female and plans to become pregnant during the course of the study.

          7. Subject has had a hypoglycemic seizure within the past 6 months prior to enrollment.

          8. Subject has had hypoglycemia resulting in loss of consciousness within the past 6
             months prior to enrollment.

          9. Subject has had an episode of diabetic ketoacidosis (DKA) within the past 6 months
             prior to enrollment.

         10. Subject has a history of a seizure disorder.

         11. Subject has central nervous system or cardiac disorder resulting in syncope.

         12. Subject has a history of myocardial infarction, unstable angina, coronary artery
             bypass surgery, coronary artery stenting, transient ischemic attack (TIA),
             cerebrovascular accident (CVA), angina, congestive heart failure, ventricular rhythm
             disturbances or thromboembolic disease

         13. If subject is 7-80 years of age, subject has a hematocrit (Hct) more than 10% below
             the lower limit of normal reference range (please note that patients may use prior
             blood draw from routine care as long as done within 6 months of screening and report
             of lab placed with subject source documents).

         14. Subject has a history of adrenal insufficiency.

         15. Subject is a member of the research staff involved with the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shannon Bondy</last_name>
    <phone>818-576-4912</phone>
    <email>shannon.bondy@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robin Mottackel</last_name>
    <phone>818-576-4886</phone>
    <email>robin.e.mottackel@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AMCR Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Bedolla</last_name>
      <phone>760-460-1537</phone>
      <email>ybedolla@amcrinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Timothy Bailey, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sansum Diabetes Research Institute</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Farfan</last_name>
      <phone>805-335-0411</phone>
      <email>cfarfan@sansum.org</email>
    </contact>
    <investigator>
      <last_name>Kristin Castorino, D.O.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SoCal Diabetes</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Halvorson</last_name>
      <phone>310-560-8376</phone>
      <email>Halvorson@socaldiabetes.com</email>
    </contact>
    <investigator>
      <last_name>Kevin Kaiserman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Morimoto</last_name>
      <phone>925-930-7267</phone>
      <email>cmorimoto@diabloclinical.com</email>
    </contact>
    <investigator>
      <last_name>Mark Christiansen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Childhood Diabetes</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cari Berget</last_name>
      <phone>303-724-8977</phone>
      <email>Cari.Berget@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Slover, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Diabetes</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christie Beatson</last_name>
      <phone>303-724-6761</phone>
      <email>Christie.beatson@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Satish Garg, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Rodriguez</last_name>
      <phone>813-974-5499</phone>
      <email>Janetrodriguez@usf.edu</email>
    </contact>
    <investigator>
      <last_name>Dorothy Shulman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brooke Narron</last_name>
      <phone>404-355-4393</phone>
      <phone_ext>362</phone_ext>
      <email>BNarron@atlantadiabetes.com</email>
    </contact>
    <investigator>
      <last_name>Bruce Bode, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Diabetes and Osteoporosis Center</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Harston</last_name>
      <phone>208-528-9657</phone>
      <email>will.harston@idahomed.com</email>
    </contact>
    <investigator>
      <last_name>David Liljenquist, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AM Diabetes and Endocrinology Center</name>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <zip>38133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lesley Draffin</last_name>
      <phone>901-531-6236</phone>
      <email>ldraffin@amdiabetes.net</email>
    </contact>
    <investigator>
      <last_name>Kashif Latif, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes &amp; Endocrinology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78749</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Lopez</last_name>
      <phone>512-334-3505</phone>
      <phone_ext>3</phone_ext>
      <email>elopez@texasdiabetes.com</email>
    </contact>
    <investigator>
      <last_name>Lindsay Harrison, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Center for Diabetes Technology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stacey Anderson, M.D.</last_name>
      <phone>434-760-0201</phone>
      <email>SG4C@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Stacey Anderson, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center, Inc.</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Hughes</last_name>
      <phone>425-271-1720</phone>
      <phone_ext>15</phone_ext>
      <email>khughes@rainier-research.com</email>
    </contact>
    <investigator>
      <last_name>Ronald Brazg, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 12, 2020</study_first_submitted>
  <study_first_submitted_qc>June 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

